Action potentials in neonatal rat cardiomyocytes
Cell-based study · Cultured neonatal Wistar rat ventricular cardiomyocytes under normoxia or CoCl2-induced chemical hypoxia [2]
Empagliflozin shortened beat-rate-corrected APD30, APD50 and APD90 under both conditions. Resting membrane potential and action potential amplitude were unchanged.
| Endpoint | Reported result | Reference |
|---|---|---|
| Beat-rate-corrected action potential duration at 90% repolarization | mean ± SEM; ms Normoxia, EMPA vs vehicle: 244 ± 4 vs 259 ± 4 ms, P < 0.05; chemical hypoxia: 271 ± 5 vs 292 ± 4 ms, P < 0.01 | [2] |
| Resting membrane potential and action potential amplitude | reported comparison No difference reported between EMPA and vehicle under either condition | [2] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 µM
- Exposure duration
- 24 h
- Method
- EMPA exposure after a 4 h, 200 µM CoCl2 challenge where applicable; intracellular microelectrode recordings
- Vehicle
- DMSO
- Reported limits
- Final DMSO fraction not identified in the selected methods.
Methods and source locations
Compound reported in the paper: Empagliflozin; Compound label in the paper: EMPA
Applies to the named research compound in this model; does not validate the current Adooq lot, formulation or clinical efficacy.
Methods: Rat neonatal cardiomyocytes isolation and culture; Action potential recordings; Statistical analyses. Results: Empagliflozin reduced action potential duration; Figure 3A–F and caption
Beat-rate-corrected action potential duration at 90% repolarization: Intracellular microelectrodes; unpaired t-test or Mann–Whitney test per figure/methods — Methods: Rat neonatal cardiomyocytes isolation and culture; Action potential recordings; Statistical analyses. Results: Empagliflozin reduced action potential duration; Figure 3A–F and caption
Resting membrane potential and action potential amplitude: Figure 3E–F; no exact values reconstructed from the plots — Methods: Rat neonatal cardiomyocytes isolation and culture; Action potential recordings; Statistical analyses. Results: Empagliflozin reduced action potential duration; Figure 3A–F and caption